Stavine

Quick links to important sections

Stavine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stavine

Quick Facts

Property Description
Active ingredient Simvastatin
Form Film-coated tablet
Pharmacological class Statin / HMG-CoA reductase inhibitor
General purpose Lipid-modifying agent (lowers “bad” cholesterol)
Origin Semi-synthetic compound

What is Stavine?

What Type of Medicine is Stavine?

Stavine is a prescription-only medication whose active compound is Simvastatin, classifying it as a statin, or HMG-CoA reductase inhibitor. This designation means it belongs to the class of lipid-modifying agents used to manage high cholesterol. Stavine is a well-established therapy for managing hypercholesterolemia. Statins are a primary class of drugs used to lower blood lipids, and this medication is a foundational, clinically recognized therapy for managing blood fat levels. Simvastatin itself is classified as a semi-synthetic derivative of a fermentation product, chemically modified to enhance its therapeutic action within the body. Stavine is manufactured as a single-active-ingredient product designed for oral administration and is supplied as a **film-coated tablet.

Stavine Composition and General Purpose

The general therapeutic purpose of Stavine is to serve as a hypocholesterolemic drug by directly targeting the body's internal cholesterol synthesis. The mechanism works by competitively inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting step in the liver's production of cholesterol. This action addresses the core biochemical process of cholesterol creation. The medication is commonly used in scenarios requiring the long-term, systemic management of abnormal lipid levels. By blocking this enzyme, the medication significantly reduces the production of cholesterol and helps lower the concentration of Low-Density Lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol, in the bloodstream. This action is essential for achieving and maintaining a healthier overall lipid profile.

Regulatory References

  1. NIH StatPearls
  2. MedlinePlus

What side effects are possible with Stavine?

Possible Side Effects and Safety Information

Stavine's official safety profile, as documented in regulatory sources, classifies adverse reactions by the affected body system and frequency of occurrence.


Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Common (ge 1/100 to < 1/10) Headache, myalgia (muscle pain), gastrointestinal disturbances (constipation, abdominal pain, flatulence).
Uncommon (ge 1/1,000 to < 1/100) Dizziness, paresthesia (tingling), rash, pruritus (itching).
Rare (ge 1/10,000 to < 1/1,000) Rhabdomyolysis, myopathy, hepatitis/jaundice, anemia.
System-Organ Classes Musculoskeletal, Hepatobiliary, Gastrointestinal, and Nervous System Disorders.

Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reactions officially documented include Rhabdomyolysis and Myopathy, which represent serious forms of muscle toxicity and are associated with a potential risk of acute renal failure. Reports also include rare cases of fatal and non-fatal Hepatic Failure and Hypersensitivity Syndrome.

Use is contraindicated in patients with active liver disease or unexplained persistent elevations of liver enzymes, as well as during pregnancy and lactation.


Time- and Population-Related Safety Patterns

The risk of muscle toxicity is explicitly documented to be related to both dose and exposure duration. For instance, the highest dose (80 mg) carries a disproportionately higher risk of myopathy, particularly during the first year of use, and is therefore restricted in regulatory labeling. The elderly (age 65 years and older) and patients of Chinese descent may be at an increased risk of myopathy, as noted in official prescribing information.

Overdose and Emergency Response

Stavine Overdose and when to seek help

Overdose Scope (Official Regulatory Information) Description
Documented Presentations Reports of acute overdosage are rare. Symptoms in reported cases, which included ingestions up to 3.6 g, were non-specific and often involved mild gastrointestinal effects. Official labeling notes the primary risk is tied to the drug class's known potential for muscle and liver toxicity.
Severity and Outcomes All patients in the reported cases of acute accidental overdose resulted in recovery without sequelae (long-term adverse effects). No specific treatment-limiting toxicity is documented in the context of a single acute overdose.
Antidote Availability There is no known specific antidote for Simvastatin (Stavine) overdose documented in official regulatory labeling.

Emergency Response and Management

Required Actions (Label-Derived Phrasing Only) Details
When to Seek Help Seek immediate medical attention for suspected or confirmed overdosage. Contacting a regional poison control center is also a mandated procedure following a significant acute ingestion.
Management Measures Management involves adopting symptomatic and supportive measures. The benefit of standard procedures like gastric decontamination is considered uncertain due to limited data on absorption and reported cases.
Required Monitoring Clinical observation, including monitoring of liver function and Creatine Kinase (CK) levels, is recommended in a healthcare setting as part of supportive care. Hemodialysis is not expected to be an effective method for drug clearance.

Therapeutic Uses of Stavine

Stavine is commonly used to provide long-term therapeutic support by addressing two primary health concerns: managing abnormal blood fat levels and reducing the risk of major cardiovascular events.

The medication is considered relevant for core therapeutic areas which include high Low-Density Lipoprotein cholesterol (LDL-C), elevated triglycerides, and mixed dyslipidemia.


Key Therapeutic Contexts

This medication assists in addressing clusters of elevated markers and symptoms related to systemic imbalance. It is applied in contexts involving heightened systemic burden for patients at high risk due to conditions marked by increased physiological stress, such as established Coronary Heart Disease (CHD) or diabetes mellitus.

A key therapeutic benefit may assist with the reduction of serious, life-threatening complications. This long-term use supports general well-being by contributing to the reduction of major complications, including non-fatal heart attacks and strokes.


Quick Fact Block

Quick Fact: Relief for Systemic Imbalance
Stavine contributes to easing the overall symptom load by targeting and lowering LDL-C and triglycerides, which are key biochemical markers of vascular risk.

Eligibility and Restrictions for Use

Stavine is officially intended for use in adults and in adolescent patients aged 10 years and older who are diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH). Eligibility is strictly governed by regulatory rules that establish both absolute prohibitions and conditional use limitations.

Contraindicated Populations

The medication is contraindicated (must not be used) in patients with active liver disease or unexplained, persistent elevations in hepatic transaminase levels. Use is also prohibited in women who are pregnant or may become pregnant, and in nursing mothers. Additionally, Stavine is contraindicated when taken alongside certain strong inhibitors of the CYP3A4 enzyme (such as specific antifungals) and with medications including gemfibrozil, cyclosporine, or danazol.

Restricted and Special Populations

The 80 mg daily dose is restricted and must not be initiated in new patients; it is reserved only for those who have taken it chronically without evidence of muscle toxicity. Use requires caution in populations with severe renal impairment or uncontrolled hypothyroidism. The official label identifies patients of advanced age (ge 65 years) and those of Chinese ancestry as having predisposing risk factors, requiring heightened caution. The safety and effectiveness of Stavine have not been established in children younger than 10 years of age.

What should I know about interactions with other medicines?

Stavine's interaction profile is documented to be highly reliant on managing its systemic exposure through two primary pathways. The drug is metabolized by the enzyme CYP3A4 and is a substrate of the OATP1B1 transporter. Inhibition of either pathway leads to a significant increase in the active drug's concentration in the blood.


Interaction Restrictions and Constraints

Co-administration with strong CYP3A4 inhibitors (such as Itraconazole and Clarithromycin) is officially contraindicated. Other prohibited combinations include Cyclosporine, Danazol, and Gemfibrozil. Several interacting agents require a mandatory dose cap on Stavine. For example, the dose is restricted to 10 mg once daily when co-administered with Verapamil or Diltiazem, and to 20 mg once daily with Amiodarone or Amlodipine. A pharmacodynamic interaction exists with agents like Colchicine and lipid-modifying doses of Niacin (ge 1 g/day), which increase the documented risk of adverse muscle effects.


Substance and Population Notes

Consumption of large quantities of grapefruit juice is officially discouraged as it can raise Stavine's plasma levels. Furthermore, Stavine must be administered at least 2 hours before or 4 hours after Bile Acid Sequestrants to prevent absorption interference. Certain populations, including Chinese patients and those with the SLCO1B1 genetic variant, have documented heightened vulnerability to interaction-related muscle adverse events.

Mechanism of Action

How Stavine Works

Stavine's mechanism begins with the active ingredient performing competitive inhibition of the HMG-CoA reductase enzyme, the central regulator of the mevalonate pathway in the liver. By blocking this primary enzymatic step, the drug immediately suppresses the cell's internal production of both cholesterol and non-sterol isoprenoid molecules, initiating a subsequent cellular and physiological response.


The resulting deficit in intracellular cholesterol triggers a homeostatic signal that significantly increases the number of Low-Density Lipoprotein (LDL) Receptors displayed on the surface of liver cells. This enhanced receptor density accelerates the rate at which LDL-C particles are captured, internalized, and removed from the bloodstream, which facilitates a subsequent reduction in circulating cholesterol concentration.


Independent of cholesterol reduction, the suppression of isoprenoid intermediates modulates downstream signaling proteins (GTPases), which modulates the function of the vascular endothelium. This mechanistic domain is associated with the modulation of localized vascular inflammatory signaling and influences the functional state of the blood vessel walls.

Dosage and Administration Information

How to use Stavine

Stavine is provided as a film-coated tablet for oral administration and is integrated into long-term therapeutic plans. The dosage is taken once daily in the evening, regardless of meal consumption. This specific timing aligns with the procedural usage guidelines for this class of medicine.

The standard starting dose for adults is typically 20 mg or 40 mg once daily, with a general maintenance range of 5 mg to 40 mg. Dosage adjustments occur at intervals of four weeks or more. Critically, the maximum recommended dose for newly initiated patients is 40 mg, and the 80 mg dose must not be initiated in any new user.

Procedural guidelines define specific administration constraints for certain contexts. For patients with severe renal impairment, the recommended starting dose is limited to 5 mg once daily. Furthermore, specific lower maximum daily doses are established when Stavine is co-administered with particular medications. If a dose is missed, the next dose should be taken as scheduled, and a doubled dose should not be taken under any circumstances to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Stavine (Simvastatin)

The evidence supporting the evaluation of Stavine (Simvastatin) is drawn from an extensive research base, primarily composed of large-scale, long-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews and Meta-analyses. This body of research has been used by regulatory bodies to characterize how the regimen was observed to affect key health markers and clinical outcomes in the studied populations.


Evidence for Modification of Blood Lipids (Dyslipidemia)

Research exploring Stavine has been conducted in short- to intermediate-term Randomized Controlled Trials (RCTs). These studies typically involved Adults with elevated levels of "bad" cholesterol, known as Low-Density Lipoprotein Cholesterol (LDL-C), or elevated triglycerides, as well as those with mixed dyslipidemia. Researchers focused on measuring specific lipid biomarkers as outcomes related to systemic or functional imbalance. Trials consistently reported patterns related to measured shifts in LDL-C and total cholesterol in the studied groups. The long-term impact on clinical events is addressed in separate, longer-duration trials; the long-term effects are not fully established based on these lipid-specific trials alone.


Evidence for Cardiovascular Event Risk Reduction

The research for Stavine has largely focused on major, multi-year Randomized Controlled Trials (RCTs) that have tracked patients for many years. These studies were designed to measure the incidence of serious clinical outcomes, known as Major Vascular Events (MVEs). The MVEs tracked were the primary endpoints examined in the studies, including non-fatal heart attack, stroke (fatal and non-fatal), and the need for heart or blood vessel procedures. Studies monitored adult populations who were at high cardiovascular risk, including patients with prior cardiovascular events or those with conditions such as diabetes mellitus. Findings describe patterns indicating a lower event rate for the composite Major Vascular Event endpoint in the studied groups over follow-up periods that often lasted around five years. Reports from the trials described consistency in the observed patterns of event rates across a wide range of high-risk participants evaluated.


Research Gaps and Areas of Uncertainty

While Stavine has a substantial evidence base, official and peer-reviewed scientific bodies acknowledge several areas where research is still evolving or data are limited. Comparative evidence is limited from large-scale, long-term, head-to-head RCTs that directly compare Stavine's outcomes against some other commonly available lipid-modifying agents. Subgroup findings are uncertain regarding the benefit of therapy for patients whose pre-existing cardiovascular risk is consistently low. Furthermore, some studies examining the highest dose of Stavine (80 mg) have described patterns related to reports indicating potential differences in muscle-related outcomes when compared to lower doses, which has led to regulatory review of that specific strength.

Key Studies & References

  1. Simvastatin: StatPearls
  2. Statins: MedlinePlus
  3. Efficacy and safety of statins for primary prevention of cardiovascular disease in elderly: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Stavine (FAQ)

Q: Is it safe to use over-the-counter pain relievers (like ibuprofen or acetaminophen) while taking Stavine?

Official regulatory documents list several specific medications and drug classes known to interact with Stavine (Simvastatin). While common over-the-counter pain relievers are generally not named as major contraindications, official guidance emphasizes the importance of disclosing all medications, including non-prescription products, to a healthcare provider before starting treatment.

Q: Can Stavine interact with common vitamins or herbal supplements?

Yes, official patient information confirms that some non-prescription products, including high doses of niacin and certain herbal supplements, may potentially interact with Stavine. Official documents state that it is important to inform a doctor or pharmacist about all medications, vitamins, and herbs being used to help manage safety.

Q: What is the risk of a serious allergic reaction to Stavine?

Serious allergic reactions, such as severe hypersensitivity syndrome (a widespread reaction) or anaphylaxis (a severe, whole-body reaction), are officially documented. Official product information lists these as rare but possible adverse events associated with the drug class.

Q: What are the possible signs that Stavine is not working for a patient?

Stavine is designed for the long-term management of high blood lipids. A lack of efficacy is typically verified by a healthcare provider using laboratory blood tests (lipid panels), as the drug works internally to lower cholesterol production rather than by causing immediate, noticeable symptoms.

Q: Does Stavine affect or show up on common laboratory blood tests?

Yes, regulatory documents note that Stavine can affect certain lab values. Monitoring of liver enzymes (transaminases) is part of treatment, and monitoring of creatine phosphokinase (CPK) levels may be advised if muscle-related symptoms occur.

Q: Is Stavine associated with weight gain or weight loss?

Official adverse reaction lists for Stavine generally include muscle pain and gastrointestinal issues. However, weight gain or weight loss are not typically listed among the common or frequently reported side effects in the official product labeling.

Q: Can the effectiveness of Stavine be reduced by certain lifestyle factors?

Official patient guidelines recommend that Stavine be used as a complement to a low-fat, low-cholesterol diet. This suggests that dietary choices are an important supporting factor that helps the medication achieve its full intended effect on blood lipids.

Q: What should I do if I suspect an interaction between Stavine and another medicine?

Regulatory guidance and patient safety information emphasize the importance of promptly reporting any unusual symptoms like muscle pain, tenderness, or weakness. Seeking immediate medical attention is advised if signs of a serious problem occur.

Q: Is Stavine the same type of medicine as [similar drug name]? What's the general difference?

Stavine (Simvastatin) belongs to the drug class known as statins (HMG-CoA reductase inhibitors). Official information indicates that Simvastatin is an established therapy that is classified as a prodrug, meaning it is activated only after being absorbed by the liver, which is a key general characteristic that differentiates it from some other statins.

Q: Are there any known interactions between Stavine and cannabis products (e.g., CBD)?

The active compound in certain cannabis products, such as Cannabidiol (CBD), has been noted to increase liver enzyme levels. Because Stavine is processed by the liver, it is important to note the need for caution and potential monitoring for signs of liver dysfunction when used alongside such products.

Q: Is Stavine considered a 'new' drug, or has it been available for a long time?

Stavine's active ingredient, Simvastatin, is considered an established therapy in its class. The drug was initially approved in the U.S. in 1991.

Q: Is it normal to experience vivid dreams or sleep changes when first starting Stavine?

Official safety reviews have examined reports of sleep disturbances, including insomnia and nightmares, in the drug class. These are listed as possible, but less common, adverse events with some statin medications.

Q: Is it true that Stavine can cause dry mouth or constipation?

Regulatory documents list constipation as a common adverse reaction associated with Stavine. However, dry mouth is generally not listed among the common or frequently reported side effects in the official product labeling.

Q: What is the expected half-life of Stavine in the body?

Pharmacokinetic data in the official product information indicates that the half-life of the active form of Stavine (Simvastatin acid) in the body is approximately 1 to 2 hours.

Q: How does Stavine affect the central nervous system?

The drug class is associated with potential effects on the nervous system. Officially documented reports include occurrences of cognitive impairment (such as confusion or memory loss), which are usually described as not serious and reversible upon stopping treatment. Other effects under the nervous system class, such as dizziness and headache, are also mentioned in official documentation.

How should Stavine be stored and disposed of?

The storage and disposal of Stavine (simvastatin) tablets are strictly defined by regulatory requirements to ensure product integrity and public safety.

Official Storage and Disposal Statements

Requirement Official Stipulation
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Container Keep in the original container and maintain it tightly closed to protect the tablets from moisture and light.
Child Safety Keep the medicine out of the sight and reach of children at all times.
Disposal The preferred method for unneeded or expired tablets is a drug take-back program.
Waste Restriction Do not flush down the toilet or pour into a sink. If a take-back is unavailable, mix the tablets with an undesirable substance (e.g., dirt) and place the mixture into a sealed bag for disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stavine found in:

A-Z Index: